Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Good news for pregnant patients on dupilumab: a prospective registry found no significant increase in major birth defects or other adverse outcomes compared to unexposed groups. The Dupilumab Pregnancy Exposure Registry tracked 539 pregnancies over five years, offering some of the most robust safety data yet for this widely used biologic. Researchers say the findings are reassuring, though more studies are still needed.
Dupilumab gets a pregnancy safety green light — with caveats
Pregnant women and their doctors can breathe a little easier: the Dupilumab Pregnancy Exposure Registry, presented at the EADV 2026 Congress, found no significant increase in major structural birth defects or other adverse pregnancy outcomes among women who used dupilumab (Dupixent) for atopic dermatitis or asthma. The findings held up across multiple comparison groups — including disease-matched women who didn't take the drug and healthy pregnant women — lending credibility to the results.
The registry, run through UCSD's MotherToBaby program, tracked 539 pregnancies from 2018 to 2024. Nearly 70% of dupilumab-exposed women took the drug from the first trimester onward, which researchers say actually strengthens the data. One notable finding: dupilumab-exposed pregnancies showed a roughly threefold higher risk of low birth weight, but researchers believe this likely reflects the severity of the underlying maternal disease rather than the drug itself.
By the Numbers
Why it matters: Up to 12% of women of reproductive age have atopic dermatitis or asthma, and many need treatment during pregnancy. With limited safety data historically available, clinicians and patients have faced difficult decisions. This registry provides much-needed, real-world evidence to guide those conversations.
